Four Products of GP (HK) that Obtained Consistency Evaluation Approvals, Namely Sodium Bicarbonate Tablets, Trimetazidine Tablets, Finasteride Tablets and Captopril Tablets, Have Successfully Won the Bids in the Third Batch of National Centralized Drug Procurement
(August 20, 2020, Hong Kong) China Grand Pharmaceutical and Healthcare Holdings Limited (“GP (HK)” or the “Company”, together with its subsidiaries, collectively referred to as the “Group”, stock code: 00512) is pleased to announce four products of the Group, which obtained consistency evaluation approvals, have all successfully won the bids in the third batch of national centralized drug procurement. Details of the relevant bidding results are stated below:
|Product||Specification and Packaging||Pricing Unit|
|Sodium Bicarbonate Tablets||0.5g*100 tablets||Bottle|
|Trimetazidine Tablets||20mg*60 tablets||Box|
|Finasteride Tablets||5mg*28 tablets||Box|
|Captopril Tablets||25mg*100 tablets||Bottle|
The Group believes that winning the bids for the four aforementioned products will help to expand the shares of these products in the domestic market and grow its brand influence among doctors and patients.